Macular Degeneration
Conditions
Brief summary
To assess genetic features and intraocular cytokine profiles of non-responders to anti-VEGF treatment of exudative age-related macular degeneration. Also to assess necessity and frequency of pro re nate medical re-treatment.
Interventions
DRUGRanibizumab
upload (three monthly injections), re-treatment as needed
Sponsors
University of Cologne
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* active subfoveal CNV related to exudative age-related macular degeneration (all subforms) * age \> 60 years * visual acuity \> 20/400 * no previous treatment for AMD
Exclusion criteria
* any previous AMD therapy * other CNV types (myopic, parapapillary) * contraindication for ranibizumab treatment * prior study participation for AMD * pregnancy / premenopausal women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Visual acuity | 2 years | Change in visual acuity within the observation period |
Secondary
| Measure | Time frame |
|---|---|
| Association between treatment response and genotype | 2 years |
| Changes in OCT central retinal thickness / retinal volume | 2 years |
| Association between treatment application delay and visual outcome | 2 years |
| Association between re-treatment necessity / frequency and intraocular cytokine profiles | 2 years |
Countries
Germany
Outcome results
None listed